Preferred first-line (1L) treatment for metastatic urothelial carcinoma (mUC) after prior immune checkpoint inhibitor (ICI) therapy: Results from a national survey.

Authors: Ali Raza Khaki, Priyanka V. Chablani, Karine Tawagi, Petros Grivas, Jeannie Hoffman-Censits, Matthew D. Galsky, Shilpa Gupta, Vadim S. Koshkin, Elizabeth R. Plimack, Jonathan E. Rosenberg, Peter H. O'Donnell

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.e16570

Source: Full article

---

Abstract

e16570